Inspections Turn Up Manufacturing Lapses FDA inspection letters to certain foreign makers of active pharmaceutical ingredients have cited manufacturing lapses that include residue left on equipment, poor control of water systems and failures in sterile processing
Sharing a 94% structural homology with native human GLP-1, Semaglutide is distinguished by three modifications: 1) amino-acid substitutions at position 8 (alanine to -aminoisobutyric acid or Aib) and position 34 (lysine to arginine), and acylation of the lysine in position 26 with a spacer consisting of two 8-amino-3,6-dioxaoctanoic acid (ADO) moieties, a glutamic acid moiety, and a C-18 fatty di-acid side chain (Lau et al., 2015)
As a result, GLP-1 coverage for medically accepted FDA-approved indications other than obesity is required while access to GLP-1s to treat obesity under Medicaid is currently limited
The key was consistency, not intensity
Minireview: the glucagon-like peptides
Prices currently start at about $149 and can be higher depending on the doses
